Long-term Follow-up study for relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL) patients previously treated with OC-1 cells.
ESTADO CLÍNICO
Reclutando
FASE/S DEL ENSAYO
Fase III
PATOLOGÍA
Leucemia mieloide aguda, Linfoma, Enfermedad de células falciformes, Linfoma Folicular, Micosis Fungoide, Trasplante de progenitores hematopoyéticos, Terapia celular y T-CARs, --> Otros, Linfoma no Hodgkin, Leucemia
FECHA DE APERTURA
Abril, 2025
FECHA DE CIERRE
,
CRITERIOS DE INCLUSIÓN
Patients previously treated with at least one fraction of OC-1 cell investigational product
Patient or patients legal representative has provided signed and dated informed consent.
Patient is able to comply with the study requirements.
Patient or patients legal representative has provided signed and dated informed consent.
Patient is able to comply with the study requirements.
CRITERIOS DE EXCLUSIÓN
None. All patients who have received prior treatment with OC-1 cell investigational product are eligible for this long-term follow up (LTFU) study.
DESCRIPCIÓN
To monitor patients with primary relapsed/refractory (R/R) CD1a-positive T-ALL/LL who received OC-1 cells, for 15 years following CAR-T infusion to assess the risk of delayed adverse events (AEs).
PALABRAS CLAVE
acute lymphoblastic leukemia, autologous, autologous transplant, blastic plasmacytoid dendritic cell neoplasm (bpdcn), cutaneous t-cell lymphoma, hematopoietic stem cell transplant, langerhans cell histiocytosis, leukemia, lymphoma, mantle cell lymphoma, non-langerhans cell histiocytosis, relapsed/refractory all, sickle cell disease, stem cell, t-cell lymphoma
